晚期胃癌Claudin-18.2靶向治疗临床研究新进展

Progress in clinical research of Claudin-18.2 targeted therapy for advanced gastric cancer

胃癌是消化系统最常见的恶性肿瘤之一,多数胃癌患者在确诊时已为晚期。晚期胃癌预后差,既往以化疗为基础的治疗效果有限。近年来,随着分子生物学技术的发展,寻找影响胃癌发生与发展的关键分子、预后指标及相关治疗靶点已成为晚期胃癌治疗领域的研究热点。Claudin-18剪接变异体2(Claudin-18 isoform 2,Claudin-18.2)是极具潜力的新兴肿瘤治疗靶点,为胃癌的靶向治疗带来新的希望。靶向Claudin-18.2的药物或治疗方法种类多样,包括单克隆抗体、双特异性抗体(bispecific antibody,Bs Ab)、抗体偶联药物(antibody-drug conjugate,ADC)和嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)免疫治疗等,目前已有多项临床研究项目正在进行并取得了良好的结果。本文总结Claudin-18.2靶向治疗的临床研究进展,以期为改善晚期胃癌患者的预后提供临床依据。

Gastric cancer is one of the most common malignant tumors of the digestive system.Most gastric cancer patients are already in advanced stage when initially diagnosed.Advanced gastric cancer has a poor prognosis and has received limited benefit from chemotherapybased therapies.In the recent years,with the development of biomolecular technologies,more and more researches have set their focus on the search for key molecules that affect the progression of gastric cancer,prognostic indicators,and therapeutic targets.Claudin-18.2 is a promising novel tumor therapeutic target which brings new hope for targeted therapy for gastric cancer.Various types of Claudin-18.2-targeting drugs have been developed,including monoclonal antibody,bispecific antibody(BsAb),antibody-drug conjugate(ADC),chimeric antigen receptor T cell(CAR-T),and so on.At present,several clinical trials have been carried out and the results are encouraging.This review summarizes the progress in clinical trials of Claudin-18.2 targeted therapy,in the hope to provide reference for improving the prognosis of patients with advanced gastric cancer.